Pralatrexate for refractory mycosis fungoides in two Japanese patients.

Authors :: Teraishi M
Oguro T
Kusume E
Kobashi H
Sano H
Fujioka A
Yamamoto M
Nakajima H
Sano S
Source :: The Journal of dermatology [J Dermatol] 2021 May; Vol. 48 (5), pp. 667-671. Date of Electronic Publication: 2021 Jan 16.
Publication Year :: 2021
Abstract: Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced-stage cutaneous T-cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily-pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.<br /> (© 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)